CZ Biomed Corporation
A Biotechnology Company
Skip to content
  • Home
  • Products
  • Research
  • News
  • About Us
  • Contact Us

News

July 17, 2017 8:27 a.m. ET

Kocal Consulting Corporation Announces Collaboration with South Korea’s Largest Hospital to Develop New Cancer Treatment

November 30, 2016

Kocal Consulting Corporation Celebrates New Consulting Agreement with CZ Biomed Corp to Help Deliver Real Value to Bio-Pharm World

November 11, 2015

CZ BioMed Corp. Announces 2.5 Year Survival of Stage 4 Colon Cancer Patient.
Cancer Free After RVLYSIS

August 26, 2013

CZ BioMed Corp. Announces Successful Reduction of Prostate Cancer Tumors
More Than 50% Using PRO-RVLYSIS®

August 16, 2012

CZ BioMed Corp. Announces Licensing of Key U.S. Patent From The University of Texas Health Science Center at San Antonio Regarding the Use of Respiratory Syncytial Virus (RSV) for Anti-Cancer Oncolytic Treatments

January 25, 2012

Prostate Cancer Trials Underway Overseas PRO-RVLYSIS(R) CZ BioMed Corp.

September 22, 2011

Prostate Cancer Cure United States Patent Application – CZ BioMed Corp.

September 8, 2011

PROGRESS IN PANCREATIC CANCER CURE RESEARCH PANRVLYSIS®

Aug 23, 2011

CZ BioMed Corp. Names Internationally Renowned Dr. Ronald E. Wheeler, M.D. as Medical Director of its Scientific and Medical Advisory Boards

May 3, 2011

BREAST CANCER CURE INTERNATIONAL PATENT APPLICATION # PCT/US2011/000602 CZ BioMed Corp.

Oct 12, 2010 12:23 ET

Research for Cancer Cure — RVLYSIS® CZ BioMed Corp.

  • U.S. Patent

  • BIO 2017

  • National Cancer Conference

     
  • Latest News

    • Collaboration with South Korea’s Largest Hospital to Develop New Cancer Treatment July 17, 2017
  • RSS Cancer Research News

    • American Cancer Society Experts Present Key Research at 2022 ASCO Meeting May 23, 2022
    • American Cancer Society’s Impact Venture Capital Fund Releases Performance Results to Date May 19, 2022
      BrightEdge Impact Venture Capital Fund Reports Net Asset Value of Some $77 Million
    • New Study Finds Medicaid Expansion Increases Survival, Reduces Health Disparities for Newly Diagnosed Patients with Cancer May 18, 2022
      American Cancer Society researchers report findings suggest better access to timely and effective treatments
    • New Study Reports Need to Monitor Public Interest in Shopping and Sales of Popular Puff Bar E-cigarette Brand May 12, 2022
      American Cancer Society researchers stress health interventions to continue reducing e-cigarette use among youth
    • Collaboration Between Leading Health Organizations Aims to Improve Health Outcomes in Communities of Color May 6, 2022
      Bank of America Convenes the American Heart Association®, American Diabetes Association®, American Cancer Society and the University of Michigan School of Public Health for an Innovative Initiative to Improve Health and Health Care Across the U.S.
  • Published on Oct 13, 2016  


    Robert Andtbacka, MD, CM of the Huntsman Cancer Institute, Salt Lake City, UT discusses the use of oncolytic viruses at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria.

  • Health Care Forum “War on Cancer” (March 30th 2017-Singapore)

     
  • Announcements

    • Collaboration with South Korea’s Largest Hospital to Develop New Cancer Treatment
    • Partnerships with Bio-pharmaceutical Leaders
    • Oncolytic Virus Reduces Prostate Cancer
  • Related Articles

    Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferondependent antiviral defense - Research Article (Biomed Central)

    Childhood virus RSV shows promise against adult cancer. - Science Daily

    CZ BioMed licenses children’s virus turned anti-cancer agent. - San Antonio Business Journal
CZ Biomed Corporation
Proudly powered by WordPress.